Related Experiment Video
Updated: Jul 12, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
Nicole Conci1,2, Elisa Tassinari1,2, Valentina Tateo1,2
1Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italy.
Abstract:
Despite the significant improvements in the field of oncological treatments in recent decades, and the advent of targeted therapies and immunotherapy, urothelial carcinoma of the bladder remains a highly heterogeneous and difficult-to-treat neoplasm with a poor prognosis. In this context, owing to the new methods of genomic sequencing, numerous studies have analyzed the genetic features of muscle-invasive bladder cancer, providing a consensus set of molecular classes, to identify malignancies that may respond better to specific treatments (standard chemotherapy, immunotherapy, target therapy, local-regional treatment, or combinations) and improve the survival. The aim of the current review is to provide an overview of the current status of the molecular landscape of muscle-invasive bladder cancer, focusing our attention on therapeutic and prognostic implications in order to select the most effective and tailored therapeutic regimen for the individual patient.
Insights
Muscle-invasive bladder cancer is difficult to treat, but genomic sequencing reveals molecular subtypes. Understanding these subtypes helps tailor treatments like chemotherapy or immunotherapy for better patient survival.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Urothelial carcinoma of the bladder, particularly muscle-invasive types, presents significant treatment challenges and poor prognosis despite advances in cancer therapies.
- Current treatments including targeted therapy and immunotherapy have shown promise but require precise patient selection.
- The heterogeneity of bladder cancer necessitates a deeper understanding of its molecular underpinnings.
Purpose of the Study:
- To review the current molecular landscape of muscle-invasive bladder cancer.
- To highlight the therapeutic and prognostic implications of identified molecular subtypes.
- To guide the selection of effective, tailored treatment regimens for individual patients.
Main Methods:
- Review of recent genomic sequencing studies on muscle-invasive bladder cancer.
- Analysis of established molecular classes and their characteristics.
- Correlation of molecular subtypes with treatment response and patient outcomes.
Main Results:
- Genomic sequencing has identified distinct molecular classes within muscle-invasive bladder cancer.
- These molecular classifications offer potential for predicting response to specific therapies (chemotherapy, immunotherapy, targeted therapy).
- Tailoring treatment based on molecular profiles is crucial for improving patient survival rates.
Conclusions:
- The molecular landscape of muscle-invasive bladder cancer is complex but offers new avenues for personalized medicine.
- Understanding genetic features is key to optimizing treatment strategies and improving outcomes.
- Future research should focus on integrating molecular data into clinical decision-making for bladder cancer patients.
